Income Statement Chison Medical Technologies Co., Ltd.
Equities
688358
CNE1000076R4
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.73 CNY | -0.63% |
|
-2.74% | +15.38% |
| 12-15 | Chison Medical Technologies Delays Two IPO-Funded Projects | MT |
| 12-03 | Certain A Shares of Chison Medical Technologies Co., Ltd. are subject to a Lock-Up Agreement Ending on 3-DEC-2025. | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
Revenues | 329M | 395M | 376M | 481M | 468M | ||||
Other Revenues, Total | 4.07M | 2.9M | 5.16M | 2.95M | 572K | ||||
Total Revenues | 333M | 398M | 381M | 484M | 469M | ||||
Cost of Goods Sold, Total | 139M | 179M | 161M | 208M | 197M | ||||
Gross Profit | 194M | 219M | 220M | 275M | 272M | ||||
Selling General & Admin Expenses, Total | 56.91M | 76.15M | 81.84M | 84.26M | 92.63M | ||||
Provision for Bad Debts | 1.14M | 738K | -1.4M | 3.58M | 1.7M | ||||
R&D Expenses | 55.64M | 72.29M | 77.88M | 77.07M | 79.63M | ||||
Other Operating Expenses | -2.01M | -2.49M | -4.3M | -3.43M | -2.68M | ||||
Other Operating Expenses, Total | 112M | 147M | 154M | 161M | 171M | ||||
Operating Income | 82.21M | 72.24M | 66.22M | 114M | 100M | ||||
Interest Expense, Total | - | -68.45K | -110K | -357K | -379K | ||||
Interest And Investment Income | 27.82M | 19.59M | 16.43M | 29.6M | 37.32M | ||||
Net Interest Expenses | 27.82M | 19.52M | 16.32M | 29.24M | 36.94M | ||||
Currency Exchange Gains (Loss) | -8.54M | -6.02M | 26.13M | 5.49M | 10.48M | ||||
Other Non Operating Income (Expenses) | -274K | -374K | -383K | -384K | -626K | ||||
EBT, Excl. Unusual Items | 101M | 85.37M | 108M | 148M | 147M | ||||
Gain (Loss) On Sale Of Investments | - | 425K | -1.37M | 2.93M | 171K | ||||
Gain (Loss) On Sale Of Assets | 12.29K | 30.26M | -503K | 3.02M | 4.61M | ||||
Asset Writedown | - | -1.59M | -506K | -61.61K | - | ||||
Other Unusual Items | 10.28M | 10.08M | 9.22M | 7.94M | 4.8M | ||||
EBT, Incl. Unusual Items | 112M | 125M | 115M | 162M | 157M | ||||
Income Tax Expense | 11.88M | 12.07M | 9.29M | 15.71M | 16.34M | ||||
Earnings From Continuing Operations | 99.64M | 112M | 106M | 146M | 141M | ||||
Net Income to Company | 99.64M | 112M | 106M | 146M | 141M | ||||
Net Income - (IS) | 99.64M | 112M | 106M | 146M | 141M | ||||
Net Income to Common Incl Extra Items | 99.64M | 112M | 106M | 146M | 141M | ||||
Net Income to Common Excl. Extra Items | 99.64M | 112M | 106M | 146M | 141M | ||||
Per Share Items | |||||||||
Net EPS - Basic | 0.89 | 1.01 | 0.94 | 1.33 | 1.26 | ||||
Basic EPS - Continuing Operations | 0.89 | 1.01 | 0.94 | 1.33 | 1.26 | ||||
Basic Weighted Average Shares Outstanding | 112M | 112M | 113M | 110M | 112M | ||||
Net EPS - Diluted | 0.89 | 1.01 | 0.94 | 1.33 | 1.26 | ||||
Diluted EPS - Continuing Operations | 0.89 | 1.01 | 0.94 | 1.33 | 1.26 | ||||
Diluted Weighted Average Shares Outstanding | 112M | 112M | 113M | 110M | 112M | ||||
Normalized Basic EPS | 0.57 | 0.48 | 0.6 | 0.84 | 0.83 | ||||
Normalized Diluted EPS | 0.57 | 0.48 | 0.6 | 0.84 | 0.83 | ||||
Dividend Per Share | 0.57 | 0.36 | 0.7 | 0.8 | 1 | ||||
Payout Ratio | 80.29 | 56.9 | 37.79 | 53.58 | 63.7 | ||||
Supplemental Items | |||||||||
EBITDA | 89.83M | 80.9M | 77.6M | 125M | 112M | ||||
EBITA | 82.71M | 72.74M | 66.69M | 114M | 101M | ||||
EBIT | 82.21M | 72.24M | 66.22M | 114M | 100M | ||||
EBITDAR | 90.32M | 81.4M | 78.07M | 127M | 113M | ||||
Total Revenues (As Reported) | 333M | 398M | 381M | 484M | 469M | ||||
Effective Tax Rate - (Ratio) | 10.65 | 9.69 | 8.07 | 9.69 | 10.42 | ||||
Total Current Taxes | 12.87M | 13.19M | 11.67M | 14.93M | 15.53M | ||||
Total Deferred Taxes | -990K | -1.12M | -2.39M | 787K | 815K | ||||
Normalized Net Income | 63.26M | 53.35M | 67.68M | 92.73M | 92.04M | ||||
Interest on Long-Term Debt | - | - | - | 357K | 379K | ||||
Supplemental Operating Expense Items | |||||||||
Advertising Expense | 4.66M | 4.1M | 2.64M | 3.38M | 5.27M | ||||
Selling and Marketing Expenses | 36.8M | 47.92M | 48.54M | 49.33M | 55M | ||||
General and Administrative Expenses | 20.11M | 28.23M | 33.3M | 34.93M | 37.63M | ||||
Research And Development Expense From Footnotes | 55.64M | 72.29M | 77.88M | 77.07M | 79.63M | ||||
Net Rental Expense, Total | 497K | 495K | 470K | 1.76M | 1.77M | ||||
Imputed Operating Lease Interest Expense | - | - | 110K | 612K | 635K | ||||
Imputed Operating Lease Depreciation | - | - | 359K | 1.15M | 1.13M | ||||
Maintenance & Repair Expenses, Total | 1.6M | 1.9M | 1.75M | 3.5M | - | ||||
Stock-Based Comp., R&D Exp. (Total) | 647K | 2.4M | - | - | - | ||||
Stock-Based Comp., S&M Exp. (Total) | 1.55M | 1.46M | - | - | - | ||||
Stock-Based Comp., G&A Exp. (Total) | 239K | 344K | - | - | - | ||||
Stock-Based Comp., Other (Total) | - | - | 63.27K | -2.34M | -1.41M | ||||
Total Stock-Based Compensation | 2.44M | 4.21M | 63.27K | -2.34M | -1.41M |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















